Pharma/ Biotechnology Investments Specialist, Vasuda Capital Management

Dr. Bhavneesh Sharma, MD, MBA

Pharma/ Biotechnology Investments Specialist

Vasuda Capital Management

Equity Bottom-Up

<p>We added <a href="https://www.smartkarma.com/entities/14532" target="_blank" data-smartkarma-citation="entities:14532:1">Acorda Therapeutics Inc (ACOR US)</a> to our U.S. model portfolio (biotech/pharma) on 7/7/2016 with a price target of $51. Today, the company's management announced that it will cease development of dalfampridine in post-stroke walking difficulty due to lack of clinical efficacy. We revisited the company's pipeline in view of this latest development.</p><p>Based on sum-of-parts, risk-adjusted NPV/ DCF method, our updated price target for the common stock is $39 (95% upside potential). Phase 3 results for CVT-301 in the treatment of OFF symptoms of Parkinson's disease are expected in Q1, 2017 and could serve as an upside catalyst to the stock price.</p>

We added Acorda Therapeutics Inc (ACOR US) to our U.S. model portfolio (biotech/pharma) on 7/7/2016 with a price target of $51. Today, the company's management announced that it will cease development of dalfampridine in post-stroke walking difficulty due to lack of clinical efficacy. We revisited the company's pipeline in view of this latest development.Based on sum-of-parts, risk-adjusted NPV/ DCF method, our updated price target for the common stock is $39 (95% upside potential). Phase 3 results for CVT-301 in the treatment of OFF symptoms of Parkinson's disease are expected in Q1, 2017 and could serve as an upside catalyst to the stock price.

Acorda Therapeutics: Attacking 'OFF' Symptoms in Parkinson's Disease

United States

Acorda Therapeutics Inc. is a biotechnology company that is developing therapies for spinal cord injury and related neurological conditions, including multiple sclerosis. Additionally, Acorda is developing multiple approaches to regeneration and repair of the spinal cord and brain.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Acorda Therapeutics (ACOR US)

Acorda Therapeutics: Attacking 'OFF' Symptoms in Parkinson's Disease

We added Acorda Therapeutics Inc (ACOR US) to our U.S. model portfolio (biotech/pharma) on 7/7/2016 with a price target of $51. Today, the...

Dr. Bhavneesh Sharma, MD, MBA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)